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BACKGROUND
Genetic testing for breast cancer susceptibility is widely used, but for many genes, 
evidence of an association with breast cancer is weak, underlying risk estimates 
are imprecise, and reliable subtype-specific risk estimates are lacking.
METHODS
We used a panel of 34 putative susceptibility genes to perform sequencing on 
samples from 60,466 women with breast cancer and 53,461 controls. In separate 
analyses for protein-truncating variants and rare missense variants in these genes, 
we estimated odds ratios for breast cancer overall and tumor subtypes. We evaluated 
missense-variant associations according to domain and classification of pathoge-
nicity.
RESULTS
Protein-truncating variants in 5 genes (ATM, BRCA1, BRCA2, CHEK2, and PALB2) 
were associated with a risk of breast cancer overall with a P value of less than 
0.0001. Protein-truncating variants in 4 other genes (BARD1, RAD51C, RAD51D, and 
TP53) were associated with a risk of breast cancer overall with a P value of less 
than 0.05 and a Bayesian false-discovery probability of less than 0.05. For protein-
truncating variants in 19 of the remaining 25 genes, the upper limit of the 95% 
confidence interval of the odds ratio for breast cancer overall was less than 2.0. 
For protein-truncating variants in ATM and CHEK2, odds ratios were higher for 
estrogen receptor (ER)–positive disease than for ER-negative disease; for protein-
truncating variants in BARD1, BRCA1, BRCA2, PALB2, RAD51C, and RAD51D, odds 
ratios were higher for ER-negative disease than for ER-positive disease. Rare mis-
sense variants (in aggregate) in ATM, CHEK2, and TP53 were associated with a risk 
of breast cancer overall with a P value of less than 0.001. For BRCA1, BRCA2, and 
TP53, missense variants (in aggregate) that would be classified as pathogenic ac-
cording to standard criteria were associated with a risk of breast cancer overall, 
with the risk being similar to that of protein-truncating variants.
CONCLUSIONS
The results of this study define the genes that are most clinically useful for inclu-
sion on panels for the prediction of breast cancer risk, as well as provide estimates 
of the risks associated with protein-truncating variants, to guide genetic counsel-
ing. (Funded by European Union Horizon 2020 programs and others.)
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Genetic testing for cancer suscep-tibility is an established part of medical practice. Until recently, testing was per-
formed mainly in patients with a strong family 
history of cancer and involved a limited number 
of genes known to be associated with a high risk 
of cancer or with specific cancer syndromes. 
With the advent of affordable sequencing, test-
ing with larger panels of genes has become pos-
sible. However, for many genes on such panels, 
evidence of an association with cancer is often 
weak and accurate estimates of the cancer risks 
associated with variants are often not available.1
To better define the set of genes associated 
with breast cancer risk, we designed a panel 
consisting of 34 known or suspected breast can-
cer susceptibility genes, including genes provided 
on commercial panels. Using this panel, we se-
quenced germline DNA from more than 60,000 
women with breast cancer and more than 53,000 
controls participating in studies of the Breast 
Cancer Association Consortium (BCAC).2 We used 
these data to estimate the risks of breast cancer 
overall and tumor subtypes associated with germ-
line protein-truncating variants and rare missense 
variants in these genes.
Me thods
Studies
We included samples from women with breast 
cancer and unaffected controls participating in 
44 BCAC studies (Tables S1 and S2 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org). All the studies were 
approved by the relevant ethics review boards 
and used appropriate consent procedures. Overall, 
30 studies did not select patients or controls on 
the basis of family history (population-based stud-
ies); the remaining 14 studies oversampled patients 
with a family history of breast cancer (family-
based studies). After all quality-control steps were 
taken, 53,461 controls and 60,466 women with 
an invasive tumor (54,624 [90.3%]), in situ tumor 
(4187 [6.9%]), or tumor of unknown invasive-
ness (1655 [2.7%]) were included in the analyses. 
Of these, 48,826 patients and 50,703 controls were 
from population-based studies.
Sequence Analysis
We analyzed a panel of 34 known or suspected 
breast cancer susceptibility genes (Tables S3 and 
S4), including genes provided on commercial pan-
els. Details regarding library preparation, sequenc-
ing, variant calling, quality-control procedures, 
and variant classification are provided in the 
Supplementary Methods section in the Supple-
mentary Appendix.
Statistical Analysis
The primary analyses were burden analyses in 
which odds ratios and 95% confidence intervals 
for breast cancer associated with the presence of 
any variant in a given category were estimated by 
means of logistic regression. The two main cat-
egories were protein-truncating variants and rare 
missense variants (i.e., variants with a population 
frequency of <0.001). Missense-variant associa-
tions were evaluated according to domain and 
classification of pathogenicity. Analyses were 
also conducted according to tumor subtype, age, 
and ancestry (European vs. Asian).
We conducted separate analyses for the pop-
ulation-based studies and the family-based stud-
ies. The inclusion of studies that oversampled 
patients with a family history of breast cancer 
improves the power to detect association3 but leads 
to biased risk estimates. Therefore, we report risk 
estimates, 95% confidence intervals, and P values 
from the population-based studies but also report 
the results of association tests from all studies 
when appropriate. For protein-truncating variants 
in each gene, evidence of an association is also 
expressed in terms of Bayesian false-discovery 
probabilities, reflecting both evidence from the 
data in this study and evidence from previous 
research.4 Absolute risks were calculated by com-
bining age-specific estimated odds ratios with 
population incidences in the United Kingdom in 
2016 as a baseline.5,6 Details regarding the sta-




Risk of Breast Cancer Overall
Protein-truncating variants in 5 genes (ATM, 
BRCA1, BRCA2, CHEK2, and PALB2) were associated 
with a significant risk of breast cancer overall 
(P<0.0001) (Table 1 and Figs. 1 and 2). For these 
genes, odds ratios ranged from 2.10 to 10.57. In 
CHEK2, the c.1100delC variant accounted for ap-
proximately 80% of the protein-truncating vari-
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Table 1. Risk of Breast Cancer Overall Associated with Protein-Truncating Variants in 34 Genes in Population-Based Studies and All Studies.*
Gene
Population-Based Studies 
(48,826 patients and 50,703 controls)†
All Studies 




No. of Carriers of Protein-
Truncating Variants Odds Ratio (95% CI) P Value P Value
Women with 
Breast Cancer Controls
ABRAXAS1 17 19 0.98 (0.50–1.94) 0.96 0.93 0.1 0.98
AKT1 3 6 0.47 (0.12–1.93) 0.29 0.14 0.1 0.94
ATM 294 150 2.10 (1.71–2.57) 9.2×10−13 5.5×10−20 0.8 1.3×10−18
BABAM2 7 9 0.62 (0.23–1.71) 0.36 0.34 0.1 0.95
BARD1 62 32 2.09 (1.35–3.23) 0.00098 0.00011 0.2 0.0076
BRCA1 515 58 10.57 (8.02–13.93) 1.1×10−62 3.7×10−65 0.99 1.5×10−64
BRCA2 754 135 5.85 (4.85–7.06) 2.2×10−75 8.4×10−77 0.99 3.1×10−76
BRIP1 86 75 1.11 (0.80–1.53) 0.54 0.54 0.2 0.85
CDH1 11 12 0.86 (0.37–1.98) 0.72 0.58 0.2 0.94
CHEK2 704 315 2.54 (2.21–2.91) 3.1×10−39 3.2×10−61 0.99 1.3×10−60
c.1100delC variant 548 245 2.66 (2.27–3.11) 1.1×10−33 5.3×10−53
Other variants 156 70 2.13 (1.60–2.84) 3.0×10−7 7.4×10−10
EPCAM 14 19 0.73 (0.36–1.49) 0.39 0.13 0.1 0.95
FANCC 71 65 1.26 (0.89–1.79) 0.20 0.20 0.1 0.87
FANCM 302 300 1.06 (0.90–1.26) 0.48 0.28 0.1 0.96
GEN1 31 43 0.66 (0.41–1.06) 0.088 0.18 0.1 0.95
MEN1 2 5 0.37 (0.07–1.97) 0.24 0.64 0.1 0.95
MLH1 5 9 0.58 (0.19–1.77) 0.34 0.55 0.1 0.95
MRE11 48 55 0.88 (0.59–1.32) 0.54 0.34 0.1 0.98
MSH2 13 13 1.06 (0.47–2.36) 0.89 0.80 0.1 0.92
MSH6 39 23 1.96 (1.15–3.33) 0.013 0.021 0.1 0.55
MUTYH 232 231 1.00 (0.83–1.21) 0.99 0.88 0.1 1.00
NBN 90 103 0.90 (0.67–1.20) 0.48 0.65 0.2 0.95
NF1 31 17 1.76 (0.96–3.21) 0.068 0.011 0.2 0.25
PALB2 274 55 5.02 (3.73–6.76) 1.6×10−26 1.1×10−32 0.99 2.9×10−32
PIK3CA 3 12 0.21 (0.06–0.75) 0.016 0.19 0.1 0.94
PMS2 40 36 1.16 (0.73–1.85) 0.53 0.37 0.1 0.92
PTEN 14 6 2.25 (0.85–6.00) 0.10 0.0040 0.2 0.14
RAD50 120 121 1.08 (0.83–1.40) 0.57 0.45 0.1 0.95
RAD51C 54 26 1.93 (1.20–3.11) 0.0070 0.00026 0.3 0.0090
RAD51D 51 25 1.80 (1.11–2.93) 0.018 0.0018 0.3 0.044
RECQL 103 120 0.84 (0.64–1.10) 0.21 0.89 0.1 0.95
RINT1 32 49 0.72 (0.46–1.14) 0.17 0.31 0.1 0.96
STK11 6 5 1.60 (0.48–5.28) 0.44 0.50 0.2 0.70
TP53 7 2 3.06 (0.63–14.91) 0.17 0.015 0.8 0.033
XRCC2 15 18 0.96 (0.47–1.93) 0.90 0.81 0.1 0.98
*  BFDP denotes Bayesian false-discovery probability, and CI confidence interval.
†  The sample sizes reflect totals after quality control. Analyses for genes other than BRCA1 and BRCA2 excluded carriers of protein-truncating 
variants in BRCA1 and BRCA2; therefore, sample sizes were slightly lower in those analyses (47,522 patients and 50,475 controls in popula-
tion-based studies, and 58,728 patients and 52,976 controls in all studies).
‡  Details regarding the prior probabilities are provided in the Supplementary Methods section in the Supplementary Appendix.
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ants. The effect size for this variant (odds ratio, 
2.66; 95% confidence interval [CI], 2.27 to 3.11; 
P = 1.1×10−33 [P = 5.3×10−53 in all studies]) did not 
differ significantly from the effect size for all 
other protein-truncating variants in CHEK2 (odds 
ratio, 2.13; 95% CI, 1.60 to 2.84; P = 3.0×10−7
[P = 7.4×10−10 in all studies]), with a P value of 0.19 
for the difference in the odds ratios.
There was more modest evidence of an asso-
ciation with breast cancer overall for protein-
truncating variants in 7 other genes: BARD1
(odds ratio, 2.09; 95% CI, 1.35 to 3.23; P = 0.00098 
[P = 0.00011 in all studies]), RAD51C (odds ratio, 
1.93; 95% CI, 1.20 to 3.11; P = 0.0070 [P = 0.00026 
in all studies]), RAD51D (odds ratio, 1.80; 95% CI, 
1.11 to 2.93; P = 0.018 [P = 0.0018 in all studies]), 
PTEN (odds ratio, 2.25; 95% CI, 0.85 to 6.00; 
P = 0.10 [P = 0.0040 in all studies]), NF1 (odds ratio, 
1.76; 95% CI, 0.96 to 3.21; P = 0.068 [P = 0.011 in 
all studies]), TP53 (odds ratio, 3.06; 95% CI, 0.63 
to 14.91; P = 0.17 [P = 0.015 in all studies]), and 
MSH6 (odds ratio, 1.96; 95% CI, 1.15 to 3.33; 
P = 0.013 [P = 0.021 in all studies]) (Table 1). For 
4 of these genes (BARD1, RAD51C, RAD51D, and 
TP53), the Bayesian false-discovery probability was 
less than 0.05 (Table 1).
For the 12 genes that had evidence of an asso-
ciation with breast cancer overall, the effect size 
for protein-truncating variants did not differ sig-
nificantly between European women and Asian 
women (Table S7). Of the remaining 22 genes, all 
but 3 (AKT1, MSH2, and STK11) had an upper limit 
of the 95% confidence interval of the odds ratio of 
less than 2.0 in the population-based studies.
 Risk of Tumor Subtypes
Of the 12 genes that had evidence of an associa-
tion with breast cancer overall, 2 had a stronger 
association with estrogen receptor (ER)–positive 
breast cancer than with ER-negative breast can-
cer: ATM (odds ratio, 2.33 [95% CI, 1.87 to 2.91] 
for ER-positive disease vs. 1.01 [95% CI, 0.64 to 
1.59] for ER-negative disease; P = 0.00055 for the 
difference) and CHEK2 (odds ratio, 2.67 [95% CI, 
2.30 to 3.11] for ER-positive disease vs. 1.64 
[95% CI, 1.25 to 2.16] for ER-negative disease; 
P = 3.6×10−5 for the difference) (Fig. 2 and Table S8). 
CHEK2 also had evidence of an association with 
ER-negative, non–triple-negative breast cancer 
(odds ratio, 2.53; 95% CI, 1.75 to 3.67) but not 
with triple-negative breast cancer (odds ratio, 1.06; 
95% CI, 0.63 to 1.76) (Table S9).
Figure 1. Frequency of Protein-Truncating Variants in 34 Genes in Population-Based Studies.
Shown are percentages of women with breast cancer and controls who were carriers of protein-truncating variants in 34 genes. The 
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In contrast, for BARD1, BRCA1, BRCA2, PALB2, 
RAD51C, and RAD51D, odds ratios were higher 
for ER-negative breast cancer than for ER-positive 
breast cancer (P<0.05 for all genes). Of these 
genes, 3 had a stronger association with triple-
negative breast cancer than with ER-negative, non–
triple-negative breast cancer: BARD1 (P = 0.044), 
BRCA1 (P = 9.6×10−17), and BRCA2 (P = 7.8×10−5) 
(Table S8).
Among the genes that had no evidence of an 
association with breast cancer overall, FANCM had 
some evidence of an association with ER-nega-
tive breast cancer (P = 0.0050 in all studies) and 
FANCC had evidence of an association with triple-
negative breast cancer (P = 0.0021 in all studies) 
(Table S9).
For BRCA1, BRCA2, and PALB2, odds ratios were 
higher for invasive tumors than for in situ tumors. 
In contrast, for ATM and CHEK2, odds ratios for 
invasive tumors and in situ tumors were similar 
(Table S10).
Age Effects and Absolute Risk
In the population-based studies, odds ratios 
decreased significantly with increasing age for 
6 genes: BRCA1, BRCA2, CHEK2, PALB2, PTEN, and 
Figure 2. Risk of Breast Cancer Overall and Tumor Subtypes Associated with Protein-Truncating Variants in 34 Genes in Population-
Based Studies.
Shown are odds ratios and 95% confidence intervals (CIs) for breast cancer overall (Panel A), estrogen receptor (ER)–positive breast 
cancer (Panel B), and ER-negative breast cancer (Panel C) associated with protein-truncating variants in 34 genes. The genes are listed 
in order of decreasing estimated odds ratios for breast cancer overall.
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TP53 (P<0.01 for all genes) (Tables S11 and S12). 
Estimated absolute risks of breast cancer were 
derived by combining age-specific estimated odds 
ratios with population incidences in the United 
Kingdom (Fig. 3). For carriers of protein-truncat-
ing variants in BRCA1, BRCA2, and PALB2, the es-
timated absolute risks by 80 years of age exceeded 
the 30% threshold for high risk, as defined by 
National Institute for Health and Care Excellence 
guidelines.7 For carriers of protein-truncating vari-
ants in ATM, BARD1, CHEK2, RAD51C, and RAD51D, 
the estimated absolute risks by 80 years of age 
were within the 17 to 30% range for moderate risk.
Rare Missense Variants
There was evidence of an association with breast 
cancer overall for rare missense variants in 6 
genes: CHEK2 (odds ratio, 1.42; 95% CI, 1.28 to 
1.58; P = 2.5×10−11 [P = 2.9×10−18 in all studies]), ATM 
(odds ratio, 1.06; 95% CI, 1.00 to 1.13; P = 0.051 
[P = 0.0010 in all studies]), TP53 (odds ratio, 1.10; 
95% CI, 0.91 to 1.31; P = 0.32 [P = 0.00080 in all 
studies]), BRCA1 (odds ratio, 1.11; 95% CI, 1.02 
to 1.20; P = 0.010 [P = 0.027 in all studies]), CDH1 
(odds ratio, 1.10; 95% CI, 0.98 to 1.23; P = 0.096 
[P = 0.042 in all studies]), and RECQL (odds ratio, 
1.12; 95% CI, 1.00 to 1.26; P = 0.047 [P = 0.036 in 
all studies]) (Table 2). Of these 6 genes, 2 had a 
stronger association with ER-positive breast can-
cer than with ER-negative breast cancer (CHEK2 
[P = 9.1×10−5] and CDH1 [P = 0.012]) and 1 had a 
stronger association with ER-negative breast can-
cer than with ER-positive breast cancer (BRCA1 
[P = 0.01]). Odds ratios decreased with increasing 
age for BRCA1 (P = 0.0026), CHEK2 (P = 0.00022), 
and TP53 (P = 0.00023).
For missense variants (in aggregate) in BRCA1, 
the risk of breast cancer overall differed according 
to domain (P = 3.0×10−6); there was an increased 
risk associated with variants located in the regions 
encoding the RING domain (P = 1.0×10−6) and the 
BRCT1 domain (P = 0.00020) (Tables S13 and S14 
and Fig. S1A). For missense variants in CHEK2, 
the odds ratios did not vary according to loca-
tion (P = 0.52), such that the risk associated with 
variants within domains (P = 4.2×10−9) was simi-
lar to the risk associated with variants outside 
domains (P = 0.001) (Tables S13 and S15 and Fig. 
S1B). For ATM, there was an increased risk as-
sociated with variants in the FRAP–ATM–TRRAP 
(FAT) domain (P = 0.00019 in all studies) and the 
protein kinase domains (P = 0.00092 in all stud-
ies) (Tables S13 and S16 and Fig. S1C). There was 
no evidence of a risk associated with missense 
variants in specific domains in BRCA2 (P = 0.27) 
or PALB2 (P = 0.48) (Tables S13, S17, and S18 and 
Figs. S1D and S1E).
We specifically examined rare missense vari-
ants in BRCA1, BRCA2, and TP53 that would be 
classified as pathogenic according to clinical 
guidelines. There was clear evidence of an asso-
ciation with breast cancer overall for pathogenic 
variants (in aggregate) in each gene (odds ratio, 
16.11 [95% CI, 5.83 to 44.50] in BRCA1, 5.68 
[95% CI, 2.62 to 12.29] in BRCA2, and 2.91 
[95% CI, 1.71 to 4.98] in TP53) but not for other 
missense variants (in aggregate) in each gene 
(odds ratio, 1.06 [95% CI, 0.98 to 1.15] in BRCA1, 
0.97 [95% CI, 0.92 to 1.02] in BRCA2, and 0.94 
[95% CI, 0.77 to 1.14] in TP53) (Table S19 and 
Figs. S2A, S2B, and S2C).
Discussion
This large study, in which we evaluated coding 
variation in putative breast cancer susceptibility 
genes, involved more than 60,000 patients and 
Figure 3. Estimated Absolute Risk of Breast Cancer Associated with Protein-
Truncating Variants in 8 Genes.
Shown are absolute risks of breast cancer through 80 years of age associat-
ed with protein-truncating variants in 8 genes that had significant evidence 
of an association with breast cancer overall, on the basis of estimated odds 
ratios from population-based studies. The absolute risk was not calculated 
for TP53 because of the wide 95% confidence interval for the odds ratio 
and the known association with a substantial risk of childhood cancer. 
Baseline absolute risks were derived from population incidences in the 






























The New England Journal of Medicine 
Downloaded from nejm.org on January 27, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 7
Breast Cancer Risk Genes




(48,826 patients and 50,703 controls)*
All Studies 
(60,466 patients and 
53,461 controls)*
No. of Carriers of Rare  
Missense Variants Odds Ratio (95% CI) P Value P Value
Women with 
Breast Cancer Controls
ABRAXAS1 233 242 1.04 (0.86–1.25) 0.70 0.40
AKT1 142 156 0.96 (0.76–1.21) 0.72 0.63
ATM 2411 2471 1.06 (1.00–1.13) 0.051 0.0010
BABAM2 167 170 1.01 (0.81–1.26) 0.91 0.63
BARD1 591 616 1.00 (0.89–1.12) 0.94 0.41
BRCA1 1393 1300 1.11 (1.02–1.20) 0.010 0.027
BRCA2 2831 3038 0.98 (0.93–1.04) 0.50 0.58
BRIP1 868 961 0.95 (0.86–1.04) 0.25 0.54
CDH1 682 668 1.10 (0.98–1.23) 0.096 0.042
CHEK2 895 697 1.42 (1.28–1.58) 2.5×10−11 2.9×10−18
EPCAM 290 328 0.97 (0.82–1.14) 0.69 0.43
FANCC 597 620 0.95 (0.85–1.07) 0.42 0.80
FANCM 1434 1566 0.95 (0.88–1.02) 0.17 0.85
GEN1 701 707 1.05 (0.94–1.17) 0.38 0.25
MEN1 109 130 0.86 (0.66–1.12) 0.25 0.81
MLH1 677 711 1.02 (0.91–1.13) 0.78 0.68
MRE11 552 611 0.94 (0.84–1.06) 0.33 0.93
MSH2 908 1024 0.92 (0.84–1.01) 0.093 0.12
MSH6 1088 1155 1.00 (0.92–1.09) 0.98 0.74
MUTYH 659 702 1.00 (0.90–1.12) 1.00 0.58
NBN 665 725 0.95 (0.85–1.06) 0.37 0.71
NF1 816 899 0.94 (0.85–1.03) 0.19 0.53
PALB2 805 892 0.96 (0.87–1.06) 0.39 1.00
PIK3CA 170 205 0.83 (0.67–1.02) 0.080 0.33
PMS2 934 963 0.95 (0.87–1.05) 0.31 0.62
PTEN 68 70 1.08 (0.76–1.53) 0.65 0.48
RAD50 1046 1089 0.99 (0.91–1.08) 0.83 0.44
RAD51C 196 206 0.93 (0.76–1.14) 0.49 0.60
RAD51D 224 212 1.05 (0.86–1.27) 0.64 0.57
RECQL 656 627 1.12 (1.00–1.26) 0.047 0.036
RINT1 732 762 1.01 (0.91–1.12) 0.89 0.18
STK11 114 139 0.83 (0.64–1.07) 0.15 0.16
TP53 257 244 1.10 (0.91–1.31) 0.32 0.00080
XRCC2 207 213 1.03 (0.84–1.25) 0.80 0.53
*  The sample sizes reflect totals after quality control. The analysis for each gene excluded carriers of protein-truncating 
variants in that gene.
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53,000 controls, permitting the calculation of 
risk estimates that are more precise than those 
obtained previously. We found strong evidence 
of an association with breast cancer risk (Bayes-
ian false-discovery probability, <0.05) for protein-
truncating variants in 9 genes, with a P value of 
less than 0.0001 for 5 genes (ATM, BRCA1, BRCA2, 
CHEK2, and PALB2) and a P value of less than 0.05 
for the other 4 genes (BARD1, RAD51C, RAD51D, 
and TP53). We found that, for protein-truncating 
variants in most of these genes, the odds ratio 
differed according to breast cancer subtype. Pro-
tein-truncating variants in ATM and CHEK2 were 
more strongly associated with ER-positive disease 
than with ER-negative disease, a finding consis-
tent with earlier observations,5,8 whereas protein-
truncating variants in BARD1, BRCA1, BRCA2, 
PALB2, RAD51C, and RAD51D were more strongly 
associated with ER-negative disease than with 
ER-positive disease. None of the other 25 genes 
in the panel had a Bayesian false-discovery prob-
ability of less than 0.10. Of note, 19 genes had 
an upper limit of the 95% confidence interval of 
the odds ratio of less than 2.0, with 2.0 repre-
senting a proposed threshold for “pathogenic, 
moderate risk alleles”9; we therefore conclude 
that these genes are not informative for the pre-
diction of breast cancer risk. We confirmed that 
missense variants in BRCA1, BRCA2, and TP53 
that would be classified as pathogenic according 
to clinical guidelines are indeed associated with 
clinically significant risks. We also found that 
rare missense variants in CHEK2 overall, as well 
as variants in specific domains in ATM, are as-
sociated with moderate risk.
Our results are broadly consistent with the 
results of an analysis by Lee et al.,10 in which the 
Clinical Genome Resource (ClinGen) clinical 
validity framework was used (Table S20). Of the 
10 genes that were regarded as having definitive 
evidence of an association with breast cancer 
risk in that analysis,10 7 genes had variants as-
sociated with breast cancer risk in our analysis; 
deleterious variants in the remaining 3 genes 
(CDH1, PTEN, and STK11) are very rare and con-
fer a predisposition to specific cancer syndromes. 
Of the 18 genes that were regarded as having 
moderate, limited, or disputed evidence of an as-
sociation with breast cancer risk in that analysis, 
2 genes (RAD51C and RAD51D) had protein-trun-
cating variants associated with breast cancer risk 
in our analysis; 13 of the remaining genes had 
an upper limit of the 95% confidence interval of 
the odds ratio of less than 2.0 (and thus were 
classified as not conferring moderate or high risk 
according to our analysis), and the other 3 genes 
(MSH2, MSH6, and NF1) could not be classified. 
An association between breast cancer risk and 
variants in RAD51C and RAD51D is highly plau-
sible, given that the functions of these genes are 
related to one another, that both genes had a 
stronger association with ER-negative breast can-
cer than with ER-positive breast cancer, and that 
both genes have evidence of an association with 
ovarian cancer.11
Association analyses of rare variants are sus-
ceptible to bias. Inclusion of studies that over-
sampled patients with a family history of breast 
cancer improves the power to detect an association 
but leads to an upward bias in estimated odds ra-
tios. The expected larger effect size in the family-
based studies (as compared with the population-
based studies) was seen for protein-truncating 
variants in all the genes with evidence of an 
association with breast cancer, except BRCA1 and 
BRCA2, and was seen for missense variants in 
ATM, CHEK2, and TP53 (Tables S21 and S22). 
Protein-truncating variants in some of these 
genes are also associated with other types of 
cancer. Moreover, testing for cancer susceptibil-
ity genes in cancer genetics clinics can lead to a 
downward bias, because carriers identified through 
previous testing may be excluded. We observed a 
depletion of carriers of protein-truncating variants 
in BRCA1 and BRCA2 among women with breast 
cancer in the family-based studies. Therefore, we 
regard the estimates from the population-based 
studies to be the most reliable.
With regard to rare missense variants, the 
clearest evidence of an association with increased 
breast cancer risk was for CHEK2. For rare mis-
sense variants (in aggregate) in CHEK2, the odds 
ratio was approximately 1.4. The association was 
independent of location, which suggests that a 
large proportion of missense variants in CHEK2 
confer risk (albeit below the threshold suggested 
for “pathogenic, moderate risk alleles”9). We 
also found some evidence of an association with 
risk for rare missense variants (in aggregate) in 
ATM, BRCA1, CDH1, and TP53, with odds ratios of 
approximately 1.1 (P<0.05) for all genes. Further-
more, we found evidence of an association with 
risk for missense variants in BRCA1, BRCA2, and 
TP53 that would be classified as pathogenic ac-
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cording to standard criteria but not for other 
missense variants in these genes; the odds ratios 
for the pathogenic variants (in aggregate) were 
similar to odds ratios for protein-truncating 
variants in these genes. For ATM, evidence of an 
association with risk appeared to be restricted to 
variants located in the regions encoding the 
phosphatidylinositol 3-kinase and 4-kinase and 
FAT domains, a finding consistent with previous 
observations.12
The absolute risk estimates for protein-trun-
cating variants in previously established risk 
genes were broadly consistent with previous 
estimates, except estimates for BRCA2 and TP53, 
which were lower than risks reported in previous 
family-based studies.13-15 However, the estimate 
for TP53 in this study was based on data from 
only seven carriers and had a wide confidence 
interval. The low estimate may reflect the sig-
nificant early mortality among carriers of pro-
tein-truncating variants in TP53; alternatively, it 
is possible that the earlier family-based studies 
had overestimated the risk.16 The analysis for 
TP53 is further complicated by the possibility of 
unrecognized somatic mutations in the blood 
due to age-related clonal hematopoiesis.17-20 The 
fact that the estimate for BRCA2 was lower than 
the estimate for BRCA1 may reflect the older age 
distribution in this study, as compared with previ-
ous studies, and perhaps a disproportionately 
large effect of genetic modifiers on risk among 
BRCA2 carriers, as compared with BRCA1 carriers.
Among European women, approximately 6.8% 
of the patients and 2.0% of the controls had 
protein-truncating variants in any of the 9 genes 
associated with breast cancer risk; in addition, 
2.2% of the patients and 1.4% of the controls 
had missense variants in CHEK2. The frequency 
of protein-truncating variants among Asian wom-
en (4.4% of the patients and 1.3% of the controls) 
was lower than the frequency among European 
women; this finding is attributable to the much 
lower frequency of the c.1100delC variant in 
CHEK2 among Asian women.
The absolute risk estimates place protein-
truncating variants in BRCA1, BRCA2, and PALB2 
in the high-risk category and place protein-
truncating variants in ATM, BARD1, CHEK2, 
RAD51C, and RAD51D in the moderate-risk cate-
gory. These results may guide screening, as well 
as prevention with risk-reducing surgery or medi-
cation, in accordance with national guidelines. 
However, because breast cancer risk is influenced 
by other genetic and lifestyle factors, in addition 
to family history, the incorporation of this infor-
mation into risk models would be required to 
give appropriate estimates.21
Despite the size of this study, the evidence of 
an association with breast cancer risk for several 
of the genes we analyzed (e.g., FANCM, MSH6, 
and NF1) remains equivocal, and even for the genes 
that had a clear association with risk, the confi-
dence intervals for the risk estimates are wide. In-
corporation of pedigree data and combined analy-
ses with other studies may improve the precision 
of these estimates. In the meantime, these results 
may help to guide the clinical reporting of results 
generated by multigene-panel testing and the 
counseling of women who are undergoing genetic 
testing for breast cancer susceptibility.
Supported by the European Union Horizon 2020 research 
and innovation programs BRIDGES (grant number, 634935) 
and B-CAST (633784), the Wellcome Trust (v203477/Z/16/Z), and 
Cancer Research UK (C1287/A16563). Details regarding funding 
of specific studies are provided in the Supplementary Appendix.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Requests for individual-level data used in these analyses 
should be made through the BCAC Data Access Co-ordinating 
Committee ( bcac@ medschl . cam . ac . uk).
Appendix
The authors’ full names and academic degrees are as follows: Leila Dorling, Ph.D., Sara Carvalho, Ph.D., Jamie Allen, M.Res., Anna 
González-Neira, Ph.D., Craig Luccarini, Cecilia Wahlström, B.Sc., Karen A. Pooley, Ph.D., Michael T. Parsons, Cristina Fortuno, M.Sc., 
Qin Wang, M.Sc., Manjeet K. Bolla, M.Sc., Joe Dennis, M.Sc., Renske Keeman, M.Sc., M. Rosario Alonso, Nuria Álvarez, Belen Herraez, 
Victoria Fernandez, Rocio Núñez-Torres, Ph.D., Ana Osorio, Ph.D., Jeanette Valcich, B.Sc., Minerva Li, M.Sc., Therese Törngren, M.Sc., 
Patricia A. Harrington, Caroline Baynes, Don M. Conroy, Brennan Decker, M.D., Ph.D., Laura Fachal, Ph.D., Nasim Mavaddat, Ph.D., 
Thomas Ahearn, Ph.D., Kristiina Aittomäki, M.D., Ph.D., Natalia N. Antonenkova, M.D., D.Sc., Norbert Arnold, Ph.D., Patrick Arveux, 
Margreet G.E.M. Ausems, M.D., Ph.D., Päivi Auvinen, M.D., Heiko Becher, Matthias W. Beckmann, M.D., Sabine Behrens, Marina 
Bermisheva, Ph.D., Katarzyna Białkowska, Ph.D., Carl Blomqvist, M.D., Ph.D., Natalia V. Bogdanova, Ph.D., Nadja Bogdanova-Markov, 
M.D., Ph.D., Stig E. Bojesen, Dr.Med.Sci., Bernardo Bonanni, M.D., Anne-Lise Børresen-Dale, Ph.D., Hiltrud Brauch, Ph.D., Michael 
Bremer, M.D., Ignacio Briceno, M.D., Ph.D., Thomas Brüning, M.D., Barbara Burwinkel, David A. Cameron, M.D., Nicola J. Camp, 
Ph.D., Archie Campbell, M.A., Angel Carracedo, M.D., Jose E. Castelao, M.D., Melissa H. Cessna, M.D., Stephen J. Chanock, M.D., 
Hans Christiansen, M.D., J. Margriet Collée, M.D., Emilie Cordina-Duverger, Ph.D., Sten Cornelissen, B.Sc., Kamila Czene, Ph.D., 
Thilo Dörk, Ph.D., Arif B. Ekici, Ph.D., Christoph Engel, M.D., Mikael Eriksson, M.Sc., Peter A. Fasching, M.D., Jonine Figueroa, Ph.D., 
Henrik Flyger, Ph.D., Asta Försti, Ph.D., Marike Gabrielson, Ph.D., Manuela Gago-Dominguez, Vassilios Georgoulias, M.D., Fabian 
The New England Journal of Medicine 
Downloaded from nejm.org on January 27, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 10
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Gil, M.D., Graham G. Giles, Ph.D., Gord Glendon, M.Sc., Encarna B. Gómez Garcia, M.D., Ph.D., Grethe I. Grenaker Alnæs, M.Sc., 
Pascal Guénel, Ph.D., Andreas Hadjisavvas, Ph.D., Lothar Haeberle, Ph.D., Eric Hahnen, Ph.D., Per Hall, M.D., Ph.D., Ute Hamann, 
Ph.D., Elaine F. Harkness, Ph.D., Jaana M. Hartikainen, Ph.D., Mikael Hartman, M.D., Ph.D., Wei He, Ph.D., Bernadette A.M. Heem-
skerk-Gerritsen, Ph.D., Peter Hillemanns, M.D., Frans B.L. Hogervorst, Antoinette Hollestelle, Ph.D., Weang Kee Ho, Ph.D., Maartje J. 
Hooning, Ph.D., Anthony Howell, M.B., B.S., Keith Humphreys, Ph.D., Faiza Idris, Anna Jakubowska, Ph.D., Audrey Jung, Ph.D., 
Pooja Middha Kapoor, Ph.D., Michael J. Kerin, M.Ch., Elza Khusnutdinova, M.D., Sung-Won Kim, M.D., Ph.D., Yon-Dschun Ko, M.D., 
Veli-Matti Kosma, M.D., Vessela N. Kristensen, Ph.D., Kyriacos Kyriacou, Ph.D., Inge M.M. Lakeman, Jong Won Lee, Ph.D., Min Hyuk 
Lee, M.D., Ph.D., Jingmei Li, Ph.D., Annika Lindblom, M.D., Ph.D., Wing-Yee Lo, Ph.D., Maria A. Loizidou, Ph.D., Artitaya Lophat-
ananon, Ph.D., Jan Lubiński, M.D., Ph.D., Robert J. MacInnis, Ph.D., Michael J. Madsen, M.Stat., Arto Mannermaa, Ph.D., Mehdi Ma-
noochehri, Ph.D., Siranoush Manoukian, M.D., Sara Margolin, M.D., Ph.D., Maria Elena Martinez, Ph.D., Tabea Maurer, Dipl.Psych., 
Dimitrios Mavroudis, M.D., Catriona McLean, M.D., Alfons Meindl, Ph.D., Arjen R. Mensenkamp, Ph.D., Kyriaki Michailidou, Ph.D., 
Nicola Miller, Ph.D., Nur Aishah Mohd Taib, Kenneth Muir, Ph.D., Anna Marie Mulligan, M.B., B.Ch., Heli Nevanlinna, Ph.D., Wil-
liam G. Newman, M.D., Ph.D., Børge G. Nordestgaard, M.D., Pei-Sze Ng, Jan C. Oosterwijk, M.D., Ph.D., Sue K. Park, M.D., Ph.D., 
Tjoung-Won Park-Simon, M.D., Jose I.A. Perez, Ph.D., Paolo Peterlongo, Ph.D., David J. Porteous, Ph.D., Karolina Prajzendanc, Ph.D., 
Darya Prokofyeva, Ph.D., Paolo Radice, Ph.D., Muhammad U. Rashid, M.D., Ph.D., Valerie Rhenius, B.Sc., Matti A. Rookus, Ph.D., 
Thomas Rüdiger, Emmanouil Saloustros, M.D., D.Sc., Elinor J. Sawyer, Ph.D., Rita K. Schmutzler, M.D., Andreas Schneeweiss, Peter 
Schürmann, B.T.A., Mitul Shah, M.Sc., Christof Sohn, Melissa C. Southey, Ph.D., Harald Surowy, Ph.D., Maija Suvanto, Ph.D., Somchai 
Thanasitthichai, M.D., Ian Tomlinson, Ph.D., Diana Torres, Ph.D., Thérèse Truong, Ph.D., Maria Tzardi, M.D., Ph.D., Yana Valova, 
M.Sc., Christi J. van Asperen, Rob M. Van Dam, Ans M.W. van den Ouweland, Ph.D., Lizet E. van der Kolk, M.D., Ph.D., Elke M. 
van Veen, Ph.D., Camilla Wendt, M.D., Ph.D., Justin A. Williams, M.P.H., Xiaohong R. Yang, Ph.D., Sook-Yee Yoon, M. Pilar Zamora, 
D. Gareth Evans, M.D., Miguel de la Hoya, Ph.D., Jacques Simard, Ph.D., Antonis C. Antoniou, Ph.D., Åke Borg, Ph.D., Irene L. Andru-
lis, Ph.D., Jenny Chang-Claude, Ph.D., Montserrat García-Closas, M.D., Dr.P.H., Georgia Chenevix-Trench, Ph.D., Roger L. Milne, 
Ph.D., Paul D.P. Pharoah, Ph.D., Marjanka K. Schmidt, Ph.D., Amanda B. Spurdle, Ph.D., Maaike P.G. Vreeswijk, Javier Benitez, Ph.D., 
Alison M. Dunning, Ph.D., Anders Kvist, Ph.D., Soo H. Teo, Ph.D., Peter Devilee, Ph.D., and Douglas F. Easton, Ph.D.
The authors’ affiliations are as follows: the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care 
(L.D., S. Carvalho, J.A., K.A.P., Q.W., M.K.B., J.D., B.D., N. Mavaddat, K. Michailidou, A.C.A., P.D.P.P., D.F.E.) and Oncology (C.L., 
P.A.H., C. Baynes, D.M.C., L.F., V.R., M. Shah, P.D.P.P., A.M.D., D.F.E.), University of Cambridge, Cambridge, the Centre for Ge-
nomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine (A. Campbell, D.J.P.), and the Centre for Cogni-
tive Ageing and Cognitive Epidemiology, Department of Psychology (D.J.P.), University of Edinburgh, the Cancer Research UK Edin-
burgh Centre (D.A.C., J.F.), and the Usher Institute of Population Health Sciences and Informatics, University of Edinburgh Medical 
School (A. Campbell, J.F.), Edinburgh, the Divisions of Informatics, Imaging, and Data Sciences (E.F.H.), Cancer Sciences (A. Howell), 
Population Health, Health Services Research, and Primary Care (A. Lophatananon, K. Muir), and Evolution and Genomic Sciences, 
School of Biological Sciences (W.G.N., E.M.V., D.G.E.), University of Manchester, the NIHR Manchester Biomedical Research Unit 
(E.F.H.) and the Nightingale Breast Screening Centre, Wythenshawe Hospital (E.F.H., H.I.), Academic Health Science Centre and North 
West Genomics Laboratory Hub, and the Manchester Centre for Genomic Medicine, St. Mary’s Hospital, Manchester University NHS 
Foundation Trust (W.G.N., E.M.V., D.G.E.), Manchester, the School of Cancer and Pharmaceutical Sciences, Comprehensive Cancer 
Centre, Guy’s Campus, King’s College London, London (E.J.S.), the Institute of Cancer and Genomic Sciences, University of Birming-
ham, Birmingham (I.T.), and the Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, Univer-
sity of Oxford, Oxford (I.T.) — all in the United Kingdom; the Human Genotyping-CEGEN Unit, Human Cancer Genetic Program 
(A.G.-N., M.R.A., N.Á., B.H., R.N.-T.), and the Human Genetics Group (V.F., A.O., J.B.), Spanish National Cancer Research Center, 
Centro de Investigación en Red de Enfermedades Raras (A.O., J.B.), Servicio de Oncología Médica, Hospital Universitario La Paz 
(M.P.Z.), and Molecular Oncology Laboratory, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San 
Carlos (M. de la Hoya), Madrid, the Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigación 
Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago (A. Carracedo, M.G.-D.), and Centro de Inves-
tigación en Red de Enfermedades Raras y Centro Nacional de Genotipado, Universidad de Santiago de Compostela (A. Carracedo), 
Santiago de Compostela, the Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de Xestion Inte-
grada de Vigo–Servizo Galeo de Saúde, Vigo (J.E.C.), and Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, 
Oviedo (J.I.A.P.) — all in Spain; the Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund 
(C. Wahlström, J.V., M.L., T. Törngren, Å.B., A.K.), the Department of Oncology, Örebro University Hospital, Örebro (C. Blomqvist), 
and the Departments of Medical Epidemiology and Biostatistics (K.C., M.E., M.G., P. Hall, W.H., K.H.), Oncology, Södersjukhuset (P. 
Hall, S. Margolin), Molecular Medicine and Surgery (A. Lindblom), and Clinical Science and Education, Södersjukhuset (S. Margolin, 
C. Wendt), Karolinska Institutet, and the Department of Clinical Genetics, Karolinska University Hospital (A. Lindblom), Stockholm 
— all in Sweden; the Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD 
(M.T.P., C.F., G.C.-T., A.B.S.), the Cancer Epidemiology Division, Cancer Council Victoria (G.G.G., R.J.M., R.L.M.), the Centre for 
Epidemiology and Biostatistics, Melbourne School of Population and Global Health (G.G.G., R.J.M., R.L.M.), and the Department of 
Clinical Pathology (M.C.S.), University of Melbourne, Anatomical Pathology, Alfred Hospital (C.M.), and the Cancer Epidemiology Divi-
sion, Cancer Council Victoria (M.C.S.), Melbourne, VIC, and Precision Medicine, School of Clinical Sciences at Monash Health, Monash 
University, Clayton, VIC (G.G.G., M.C.S., R.L.M.) — all in Australia; the Division of Molecular Pathology (R.K., S. Cornelissen, M.K.S.), 
Family Cancer Clinic (F.B.L.H., L.E.K.), Department of Epidemiology (M.A.R.), and Division of Psychosocial Research and Epidemiol-
ogy (M.K.S.), the Netherlands Cancer Institute–Antoni van Leeuwenhoek Hospital, Amsterdam, Division Laboratories, Pharmacy and 
Biomedical Genetics, Department of Genetics, University Medical Center, Utrecht (M.G.E.M.A.), the Department of Clinical Genetics, 
Erasmus University Medical Center (J.M.C., A.M.W.O.), and the Department of Medical Oncology, Family Cancer Clinic, Erasmus MC 
Cancer Institute (B.A.M.H.-G., A. Hollestelle, M.J.H.), Rotterdam, the Department of Clinical Genetics, Maastricht University Medical 
Center, Maastricht (E.B.G.G.), the Departments of Human Genetics (I.M.M.L., M.P.G.V., P.D.), Clinical Genetics (C.J.A.), and Pathol-
ogy (P.D.), Leiden University Medical Center, Leiden, the Department of Human Genetics, Radboud University Medical Center, Nijme-
gen (A.R.M.), and the Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen (J.C.O.) — 
all in the Netherlands; the Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute (B.D.), 
and the Division of Cancer Epidemiology and Genetics, National Cancer Institute (T.A., S.J.C., X.R.Y., M.G.-C.), National Institutes of 
The New England Journal of Medicine 
Downloaded from nejm.org on January 27, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 11
Breast Cancer Risk Genes
Health, Bethesda, MD; the Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School (B.D.), and the Depart-
ment of Nutrition, Harvard T.H. Chan School of Public Health (R.M.V.D.), Boston; the Departments of Clinical Genetics (K.A.), Oncol-
ogy (C. Blomqvist), and Obstetrics and Gynecology (H.N., M. Suvanto), Helsinki University Hospital, University of Helsinki, Helsinki, 
and the Unit of Clinical Oncology, Kuopio University Hospital (P. Auvinen), the Institute of Clinical Medicine, Oncology (P. Auvinen), 
the Translational Cancer Research Area (J.M.H., V.-M.K., A. Mannermaa), and the Institute of Clinical Medicine, Pathology, and Foren-
sic Medicine (J.M.H., V.-M.K., A. Mannermaa), University of Eastern Finland, and the Biobank of Eastern Finland, Kuopio University 
Hospital (V.-M.K., A. Mannermaa), Kuopio — both in Finland; the N.N. Alexandrov Research Institute of Oncology and Medical Radi-
ology, Minsk, Belarus (N.N.A., N.V.B.); the Department of Gynecology and Obstetrics and Institute of Clinical Molecular Biology, 
University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel (N.A.), the Institute of Medical Biom-
etry and Epidemiology (H. Becher) and Cancer Epidemiology Group (T.M., J.C.-C.), University Cancer Center Hamburg, University 
Medical Center Hamburg-Eppendorf, Hamburg, the Department of Gynecology and Obstetrics (M.W.B., P.A.F., L.H.) and Institute of 
Human Genetics (A.B.E.), University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer 
Center Erlangen–European Metropolitan Region of Nuremberg, Erlangen, the Division of Cancer Epidemiology (S.B., A. Jung, P.M.K., 
J.C.-C.), Molecular Epidemiology Group, C080 (B. Burwinkel, H.S.), Division of Pediatric Neurooncology (A.F.), and Molecular Genet-
ics of Breast Cancer (U.H., M.M., M.U.R., D.T.), German Cancer Research Center, Molecular Biology of Breast Cancer, University 
Women’s Clinic Heidelberg, University of Heidelberg (B. Burwinkel, A.S., H.S.), Hopp Children’s Cancer Center (A.F.), Faculty of 
Medicine, University of Heidelberg (P.M.K.), and National Center for Tumor Diseases, University Hospital and German Cancer Research 
Center (A.S., C.S.), Heidelberg, the Department of Radiation Oncology (N.V.B., M. Bremer, H.C.) and the Gynecology Research Unit 
(N.V.B., T.D., P. Hillemanns, T.-W.P.-S., P.S.), Hannover Medical School, Hannover, the Institute of Human Genetics, University of 
Münster, Münster (N.B.-M.), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart (H. Brauch, W.-Y.L.), iFIT-
Cluster of Excellence, University of Tübingen, and the German Cancer Consortium, German Cancer Research Center, Partner Site 
Tübingen (H. Brauch), and the University of Tübingen (W.-Y.L.), Tübingen, Institute for Prevention and Occupational Medicine of the 
German Social Accident Insurance, Institute of the Ruhr University Bochum, Bochum (T.B.), Institute for Medical Informatics, Statistics, 
and Epidemiology, University of Leipzig, Leipzig (C.E.), Center for Hereditary Breast and Ovarian Cancer (E.H., R.K.S.) and Center for 
Integrated Oncology (E.H., R.K.S.), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, the Depart-
ment of Internal Medicine, Evangelische Kliniken Bonn, Johanniter Krankenhaus, Bonn (Y.-D.K.), the Department of Gynecology and 
Obstetrics, University of Munich, Campus Großhadern, Munich (A. Meindl), and the Institute of Pathology, Städtisches Klinikum 
Karlsruhe, Karlsruhe (T.R.) — all in Germany; the Gynecological Cancer Registry, Centre Georges-François Leclerc, Dijon (P. Arveux), 
and the Center for Research in Epidemiology and Population Health, Team Exposome and Heredity, INSERM, University Paris-Saclay, 
Villejuif (E.C.-D., P.G., T. Truong) — both in France; the Institute of Biochemistry and Genetics, Ufa Federal Research Center of the 
Russian Academy of Sciences (M. Bermisheva, E.K.), the Department of Genetics and Fundamental Medicine, Bashkir State University 
(E.K., D.P., Y.V.), and the Ufa Research Institute of Occupational Health and Human Ecology (Y.V.), Ufa, Russia; the Department of 
Genetics and Pathology (K.B., A. Jakubowska, J. Lubiński, K.P.) and the Independent Laboratory of Molecular Biology and Genetic 
Diagnostics (A. Jakubowska), Pomeranian Medical University, Szczecin, Poland; the Copenhagen General Population Study, the Depart-
ment of Clinical Biochemistry (S.E.B., B.G.N.), and the Department of Breast Surgery (H.F.), Herlev and Gentofte Hospital, Copenhagen 
University Hospital, Herlev, and the Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen (S.E.B., B.G.N.) 
— both in Denmark; the Division of Cancer Prevention and Genetics, European Institute of Oncology Istituto di Ricovero e Cura a 
Carattere Scientifico (IRCCS) (B. Bonanni), the Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazi-
one IRCCS Istituto Nazionale dei Tumori di Milano (S. Manoukian), the Genome Diagnostics Program, FIRC Institute of Molecular 
Oncology (P.P.), and the Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS 
Istituto Nazionale dei Tumori (P.R.), Milan; the Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-
Radiumhospitalet (A.-L.B.-D., G.I.G.A., V.N.K.), and the Institute of Clinical Medicine, Faculty of Medicine, University of Oslo (A.-L.B.-
D., V.N.K.), Oslo; Medical Faculty, Universidad de La Sabana (I.B.), and the Clinical Epidemiology and Biostatistics Department (F.G.) 
and Institute of Human Genetics (D.T.), Pontificia Universidad Javeriana, Bogota, Colombia; the Department of Internal Medicine and 
Huntsman Cancer Institute, University of Utah (N.J.C., M.J.M., J.A.W.), and the Intermountain Healthcare Biorepository and Depart-
ment of Pathology, Intermountain Healthcare (M.H.C.), Salt Lake City; the David Geffen School of Medicine, Department of Medicine 
Division of Hematology and Oncology, University of California, Los Angeles (P.A.F.), and Moores Cancer Center (M.G.-D., M.E.M.) and 
the Department of Family Medicine and Public Health (M.E.M.), University of California San Diego, La Jolla; the Departments of 
Medical Oncology (V.G., D.M.) and Pathology (M.T.), University Hospital of Heraklion, Heraklion, and the Department of Oncology, 
University Hospital of Larissa, Larissa (E.S.) — both in Greece; the Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum 
Research Institute of Mount Sinai Hospital (G.G., I.L.A.), the Departments of Laboratory Medicine and Pathobiology (A.M.M.) and 
Molecular Genetics (I.L.A.), University of Toronto, and the Laboratory Medicine Program, University Health Network (A.M.M.), To-
ronto, and the Genomics Center, Centre Hospitalier Universitaire de Québec–Université Laval Research Center, Québec City, QC (J.S.) 
— both in Canada; the Department of Electron Microscopy and Molecular Pathology (A. Hadjisavvas, K.K., M.A.L.), the Cyprus School 
of Molecular Medicine (A. Hadjisavvas, K.K., M.A.L., K. Michailidou), and the Biostatistics Unit (K. Michailidou), Cyprus Institute of 
Neurology and Genetics, Nicosia, Cyprus; the Saw Swee Hock School of Public Health (M. Hartman, R.M.V.D.) and the Department of 
Medicine, Yong Loo Lin School of Medicine (R.M.V.D.), National University of Singapore, the Department of Surgery, National Univer-
sity Health System (M. Hartman, J. Li), and the Human Genetics Division, Genome Institute of Singapore (J. Li), Singapore; the Depart-
ment of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia (W.K.H.), and the Breast 
Cancer Research Programme, Cancer Research Malaysia (W.K.H., P.S.N., S.-Y.Y., S.H.T.), Selangor, and the Breast Cancer Research 
Unit, Cancer Research Institute (N.A.M.T.), and the Department of Surgery, Faculty of Medicine (N.A.M.T., P.S.N., S.H.T.), University 
Malaya, Kuala Lumpur — both in Malaysia; Surgery, School of Medicine, National University of Ireland, Galway (M.J.K., N. Miller); the 
Department of Surgery, Daerim Saint Mary’s Hospital (S.-W.K.), the Department of Surgery, Ulsan University College of Medicine and 
Asan Medical Center (J.W.L.), the Department of Surgery, Soonchunhyang University College of Medicine and Soonchunhyang Univer-
sity Hospital (M.H.L.), Integrated Major in Innovative Medical Science, Seoul National University College of Medicine (S.K.P.), and the 
Cancer Research Institute, Seoul National University (S.K.P.), Seoul, South Korea; the Department of Basic Sciences, Shaukat Khanum 
Memorial Cancer Hospital and Research Center, Lahore, Pakistan (M.U.R.); and the National Cancer Institute, Ministry of Public Health, 
Nonthaburi, Thailand (S.T.).
The New England Journal of Medicine 
Downloaded from nejm.org on January 27, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 12
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
References
1. Easton DF, Pharoah PDP, Antoniou 
AC, et al. Gene-panel sequencing and the 
prediction of breast-cancer risk. N Engl J 
Med 2015; 372: 2243-57.
2. University of Cambridge and Cancer Re-
search UK. Breast Cancer Association Con-
sortium. 2020 (http://bcac . ccge . medschl 
. cam . ac . uk).
3. Antoniou AC, Easton DF. Polygenic 
inheritance of breast cancer: implications 
for design of association studies. Genet 
Epidemiol 2003; 25: 190-202.
4. Wakefield J. A Bayesian measure of 
the probability of false discovery in ge-
netic epidemiology studies. Am J Hum 
Genet 2007; 81: 208-27.
5. Schmidt MK, Hogervorst F, van Hien 
R, et al. Age- and tumor subtype-specific 
breast cancer risk estimates for 
CHEK2*1100delC carriers. J Clin Oncol 
2016; 34: 2750-60.
6. Cancer Research UK. Breast cancer 
incidence (invasive) statistics. 2020 (https://
www . cancerresearchuk . org/ health 
- professional/ cancer - statistics/ statistics 
- by - cancer - type/ breast - cancer/ incidence 
- invasive).
7. National Institute for Health and Care 
Excellence. Familial breast cancer: classi-
fication, care and managing breast cancer 
and related risks in people with a family 
history of breast cancer. November 20, 
2019 (https://www . nice . org . uk/ guidance/ 
 cg164).
8. Renault A-L, Mebirouk N, Fuhrmann 
L, et al. Morphology and genomic hall-
marks of breast tumours developed by 
ATM deleterious variant carriers. Breast 
Cancer Res 2018; 20: 28.
9. Spurdle AB, Greville-Heygate S, Anto-
niou AC, et al. Towards controlled termi-
nology for reporting germline cancer sus-
ceptibility variants: an ENIGMA report. 
J Med Genet 2019; 56: 347-57.
10. Lee K, Seifert BA, Shimelis H, et al. 
Clinical validity assessment of genes fre-
quently tested on hereditary breast and 
ovarian cancer susceptibility sequencing 
panels. Genet Med 2019; 21: 1497-506.
11. Song H, Dicks E, Ramus SJ, et al. Con-
tribution of germline mutations in the 
RAD51B, RAD51C, and RAD51D genes to 
ovarian cancer in the population. J Clin 
Oncol 2015; 33: 2901-7.
12. Tavtigian SV, Oefner PJ, Babikyan D, 
et al. Rare, evolutionarily unlikely mis-
sense substitutions in ATM confer in-
creased risk of breast cancer. Am J Hum 
Genet 2009; 85: 427-46.
13. Antoniou A, Pharoah PDP, Narod S, 
et al. Average risks of breast and ovarian 
cancer associated with BRCA1 or BRCA2 
mutations detected in case series un-
selected for family history: a combined 
analysis of 22 studies. Am J Hum Genet 
2003; 72: 1117-30.
14. Kuchenbaecker KB, Hopper JL, Barnes 
DR, et al. Risks of breast, ovarian, and 
contralateral breast cancer for BRCA1 and 
BRCA2 mutation carriers. JAMA 2017; 317: 
2402-16.
15. Hwang SJ, Lozano G, Amos CI, Strong 
LC. Germline p53 mutations in a cohort 
with childhood sarcoma: sex differences 
in cancer risk. Am J Hum Genet 2003; 72: 
975-83.
16. Fortuno C, James PA, Spurdle AB. 
Current review of TP53 pathogenic germ-
line variants in breast cancer patients out-
side Li-Fraumeni syndrome. Hum Mutat 
2018; 39: 1764-73.
17. Watson CJ, Papula AL, Poon GYP, 
et al. The evolutionary dynamics and fit-
ness landscape of clonal hematopoiesis. 
Science 2020; 367: 1449-54.
18. Boettcher S, Miller PG, Sharma R, 
et al. A dominant-negative effect drives 
selection of TP53 missense mutations in 
myeloid malignancies. Science 2019; 365: 
599-604.
19. Coffee B, Cox HC, Kidd J, et al. Detec-
tion of somatic variants in peripheral 
blood lymphocytes using a next genera-
tion sequencing multigene pan cancer 
panel. Cancer Genet 2017; 211: 5-8.
20. Coffee B, Cox HC, Bernhisel R, et al. 
A substantial proportion of apparently 
heterozygous TP53 pathogenic variants 
detected with a next-generation sequenc-
ing hereditary pan-cancer panel are ac-
quired somatically. Hum Mutat 2020; 41: 
203-11.
21. Lee A, Mavaddat N, Wilcox AN, et al. 
BOADICEA: a comprehensive breast can-
cer risk prediction model incorporating 
genetic and nongenetic risk factors. Gen-
et Med 2019; 21: 1708-18.
Copyright © 2021 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org on January 27, 2021. For personal use only. No other uses without permission. 
 Copyright © 2021 Massachusetts Medical Society. All rights reserved. 
